The International Generic and Biosimilar medicines Association (IGBA), which represents global manufacturers of generic and biosimilar medicines, welcomes the UK MHRA publication of its updated guidance on the licensing of biosimilar products (10 May 2021). This publication marks a positive milestone in the evolution of evidence requirements for biosimilar approval through the removal of the default need for a comparative efficacy trial, instead basing approval on a comprehensive comparability exercise, including a comparative pharmacokinetics (PK) trial.
13 April 2021 - The Global Diabetes Compact is a major new WHO initiative which will unite people working in diabetes prevention, treatment and care, including people living with the condition, around a common agenda.
Geneva, 11 January 2021 - IGBA, the International Generic and Biosimilar Medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), is taking over the position of IGBA Chair for 2021 from Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers.
- IGBA Launches First Global Biosimilars Week (November 2020)
- Innovative and generic & biosimilar pharmaceutical industries unite on commitment to equitable access to COVID-19 medicines and vaccines, while flagging where further help is needed from others (November 2020)
- Global Biosimilars Week: Message of the IGBA Chair (November 2020)
- Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics (24 September 2020)